Back

SLFN11 restricts escape from telomere crisis to prevent alternative lengthening of telomeres

Segura-Bayona, S.; Borel, V.; Stanage, T. H.; Maric, M.; Walter, M.; Oliveira, R. A.; Li, S.; Idilli, A. I.; Peritore, M.; Hewitt, G.; Hekkelman, M.; Snell, D. M.; Jones, S. T.; Cheshire, C.; Elezi, A.; Chakravarty, P.; Mitter, R.; Mikolajczak, A.; Gee, H. E.; Nye, E.; O'Sullivan, R. J.; Singhi, A. D.; Brummelkamp, T. R.; Cesare, A. J.; Boulton, S. J.

2025-09-10 molecular biology
10.1101/2025.09.10.675313 bioRxiv
Show abstract

The tRNA nuclease SLFN11 is epigenetically silenced in [~]50% of treatment-naive tumours and is the strongest predictor of chemoresistance but why it is frequently inactivated in cancer is unknown. To acquire immortality, cancer cells can activate alternative lengthening of telomeres (ALT), typically accompanied by ATRX loss. Here, we implicate SLFN11 in sensing telomere replication stress, triggering eradication of ATRX deficient cells prior to ALT establishment. Whereas progressive telomere shortening of cells lacking telomerase and ATRX leads to telomere crisis and cell death, SLFN11 loss confers tolerance to PML-BLM dependent ALT intermediates, permitting emergence of ALT survivors. We propose that during tumorigenesis SLFN11 inactivation is selected as means to tolerate endogenous replication stress following telomere crisis, leading to the development of therapy resistant tumours before treatment.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.